Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia

计划入组 30 人 · 首次发布于 2016 年 7 月 12 日

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

计划入组 74 人 · 首次发布于 2026 年 9 月 10 日

Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer

计划入组 225 人 · 首次发布于 2026 年 9 月 17 日

OTS-P19

Nendratareotide uzatansine

antibody-drug conjugate 3

PeptiDream

Japan

Redpharm Drug

United States

Chain Drug Consortium

United States

Avacta Develops First Dual-Payload Peptide Drug Conjugate Platform for Cancer Combination Therapy

TwoStep Therapeutics Raises $62.5M Series A and Wins FDA IND Clearance for First-in-Class Multi-Specific Peptide-Drug Conjugate TS-104

Peptide Drug Conjugates Emerge as Next-Generation Cancer Therapeutics with Over 30 Candidates in Clinical Development